Sanofi’s pure-play biopharma pivot, Dupixent-led growth, and approximately 8.2x forward P/E create an undervalued specialty champion despite pipeline and patent-cliff risks.
Overview
Sanofi SA has completed a strategic shift from a diversified healthcare group into a focused innovative biopharmaceutical company. The April 30, 2025 Opella transaction delivered approximately €10 billion of net cash while leaving Sanofi with a 48.2% stake, allowing management to concentrate on higher-margin specialty care and vaccines. **Dupixent anchors the model**, generating €15,714 million in FY2025 and €5,154 million in Q2 2026, up 37.6% at CER; COPD expansion supports a projected €25 billion of sales by 2030. Q2 net sales rose 17.8% at CER to €11,597 million, Business EPS increased 33.3% at CER to €2.09, and H1 free cash flow rose 51.5% to €3,724 million. Management raised FY2026 guidance to around 10% net sales growth at CER, with Business EPS growing slightly faster. Despite this operating strength, the stock fell to $43.46 after pipeline write-downs and concerns over second-half normalization. The forward P/E of approximately 8.2x is well below broader pharmaceutical valuations, while analysts’ average targets of approximately $54.06-$54.61 imply upside. The principal catalysts are collaboration-profit growth from Q3 2026, further Dupixent indications, pipeline readouts, and launch-portfolio expansion.